Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14477058 | 0.84 | ALDH1A1 (0.62) | ALDH1A1LMNAUSP2NPC1SMN1; SMN2 | |
| SCHEMBL11668730 | 0.84 | ALDH1A1 (0.62) | ALDH1A1LMNAUSP2NPC1SMN1; SMN2 | |
| SCHEMBL1816291 | 0.84 | ALDH1A1 (0.62) | ALDH1A1LMNAUSP2NPC1SMN1; SMN2 | |
| SCHEMBL23886458 | 0.83 | CHRM2 (0.42) | ALDH1A1LMNASMN1; SMN2MITF | |
| SCHEMBL64561 | 0.83 | CHRM2 (0.46) | ALDH1A1LMNASMN1; SMN2MITFMAPT | |
| SCHEMBL12447234 | 0.83 | TDP1 (0.48) | ALDH1A1SMN1; SMN2CYP3A4CYP2C19TDP1 | |
| SCHEMBL31757749 | 0.82 | USP2 (0.52) | ALDH1A1LMNAUSP2NPC1SMN1; SMN2 | |
| SCHEMBL9774559 | 0.81 | CHRM2 (0.49) | ALDH1A1LMNAUSP2TDP1TSHR | |
| SCHEMBL9512804 | 0.81 | ALDH1A1 (0.72) | ALDH1A1LMNAUSP2NPC1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL5967015 | 0.81 | ALDH1A1 (0.53) | ALDH1A1LMNAUSP2NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | MEDIVIR AB (SE) | 2013-01-03 | — | — | US | claimed |
| EP-2499120-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | Novadex Pharmaceuticals AB (SE) | 2012-09-19 | — | — | EP | claimed |
| WO-2011056126-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | NOVADEX PHARMACEUTICALS AB (SE) | 2011-05-12 | — | — | WO | claimed |
| EP-3625316-B1 | DISPERSANTS, METHOD OF MAKING, AND USING SAME | CHEVRON ORONITE CO (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3084152-B1 | FLUORINATED OLEFINS AS WORKING FLUIDS AND METHODS OF USING SAME | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-05-31 | — | — | EP | disclosed |
| CN-110621766-B | Dispersant, method of manufacture and use thereof | 雪佛龙奥伦耐有限责任公司 | 2021-12-24 | — | — | CN | disclosed |
| US-10815446-B2 | Dispersants, method of making, and using same | CHEVRON ORONITE COMPANY LLC (US) | 2020-10-27 | — | — | US | disclosed |
| EP-3169745-B1 | HYDROFLUOROETHER OLEFINS AND METHODS OF USING SAME | 3M INNOVATIVE PROPERTIES CO (US) | 2020-04-29 | — | — | EP | disclosed |
| EP-3625316-A1 | DISPERSANTS, METHOD OF MAKING, AND USING SAME | Chevron Oronite Company LLC (US) | 2020-03-25 | — | — | EP | disclosed |
| US-10557069-B2 | Fluorinated olefins as working fluids and methods of using same | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-02-11 | — | — | US | disclosed |
| CN-110621766-A | Dispersant, method of manufacture and use thereof | 雪佛龙奥伦耐有限责任公司 | 2019-12-27 | — | — | CN | disclosed |
| EP-3169745-A1 | HYDROFLUOROETHER OLEFINS AND METHODS OF USING SAME | 3M Innovative Properties Company (US) | 2017-05-24 | — | — | EP | disclosed |
| US-20160312096-A1 | FLUORINATED OLEFINS AS WORKING FLUIDS AND METHODS OF USING SAME | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-10-27 | — | — | US | disclosed |
| EP-3084152-A1 | FLUORINATED OLEFINS AS WORKING FLUIDS AND METHODS OF USING SAME | 3M Innovative Properties Company (US) | 2016-10-26 | — | — | EP | disclosed |
| WO-2016011220-A1 | HYDROFLUOROETHER OLEFINS AND METHODS OF USING SAME | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | MEDIVIR AB (SE) | 2013-01-03 | — | — | US | disclosed |
| EP-2499120-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | Novadex Pharmaceuticals AB (SE) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011056126-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | NOVADEX PHARMACEUTICALS AB (SE) | 2011-05-12 | — | — | WO | disclosed |
| US-5117055-A | Method for direct conversion of fluorocarbonyl group into halogenides | AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1992-05-26 | — | — | US | disclosed |
| US-4985556-A | INTERMEDIATES | AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) | 1991-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | REN, AGTR1, ACE | ALDH1A1 273/4885LMNA 2124/4885USP2 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.